SCHEMBL13650475

SCHEMBL13650475

Nc1nc(NCC2CCCNC2)c2c(n1)C(c1ccccc1)CCC2

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 2/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.52
▸ APP P05067 1/20 0.43
▸ BRD4 O60885 2/20 0.43
▸ ATAD2 Q6PL18 2/20 0.43
▸ AURKB Q96GD4 7/20 0.38
▸ SYK P43405 6/20 0.38
▸ KCNH2 Q12809 4/20 0.38
▸ METAP2 P50579 1/20 0.37
▸ EHMT2 Q96KQ7 2/20 0.37
▸ HTR2B P41595 1/20 0.36
▸ IRAK1 P51617 1/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ NOS3 P29474 1/20 0.36
▸ NOS1 P29475 1/20 0.36
▸ PBK Q96KB5 1/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13657250 0.95 HRH4 (0.53) HRH4HRH3APPBRD4ATAD2
SCHEMBL13650465 0.95 HRH4 (0.53) HRH4HRH3APPBRD4ATAD2
SCHEMBL13650456 0.92 HRH3 (0.53) HRH4HRH3APPBRD4ATAD2
SCHEMBL13650470 0.89 HRH4 (0.57) HRH4HRH3APPBRD4ATAD2
SCHEMBL13650467 0.85 HRH4 (0.51) HRH4HRH3APPBRD4IRAK4
SCHEMBL13650618 0.84 HRH4 (0.52) HRH4HRH3APPAURKBSYK
SCHEMBL13650537 0.84 HRH4 (0.52) HRH4HRH3APPAURKBSYK
SCHEMBL13650557 0.83 HRH4 (0.47) HRH4HRH3APPAURKBHTR2B
SCHEMBL13650531 0.83 HRH3 (0.53) HRH4HRH3APPEHMT2HTR2B
SCHEMBL13650552 0.83 HRH3 (0.47) HRH4HRH3APPHTR2BNOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 — — WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH4 3370/4885HRH3 3555/4885APP 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback